Generic Livalo Availability

Livalo is a brand name of pitavastatin, approved by the FDA in the following formulation(s):

LIVALO (pitavastatin calcium - tablet; oral)

  • Manufacturer: KOWA CO
    Approval date: August 3, 2009
    Strength(s): EQ 1MG BASE, EQ 2MG BASE, EQ 4MG BASE [RLD]

Has a generic version of Livalo been approved?

No. There is currently no therapeutically equivalent version of Livalo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Livalo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Quinoline analogs of mevalonolactone and derivatives thereof
    Patent 5,753,675
    Issued: May 19, 1998
    Inventor(s): Wattanasin; Sompong
    Assignee(s): Novartis Pharmaceuticals Corporation
    Quinoline analogs of mevalonolactone of the following formula are useful as anti-cholesterol synthesis agents: ##STR1## where the substituents are as defined in the specification.
    Patent expiration dates:
    • May 19, 2015
      ✓ 
      Patent use: ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Quinoline type mevalonolactones
    Patent 5,854,259
    Issued: December 29, 1998
    Inventor(s): Fujikawa; Yoshihiro & Suzuki; Mikio & Iwasaki; Hiroshi & Sakashita; Mitsuaki & Kitahara; Masaki
    Assignee(s): Nissan Chemical Industries Ltd.
    Described herein are mevalonolactone derivatives having a quinoline ring of formula (I) ##STR1## wherein the R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z variables are described therein.
    Patent expiration dates:
    • December 29, 2015
      ✓ 
      Drug product
  • Quinoline type mevalonolactones
    Patent 5,856,336
    Issued: January 5, 1999
    Inventor(s): Fujikawa; Yoshihiro & Suzuki; Mikio & Iwasaki; Hiroshi & Sakashita; Mitsuaki & Kitahara; Masaki
    Assignee(s): Nissan Chemical Industries Ltd.
    A compound of the formula ##STR1## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.
    Patent expiration dates:
    • January 5, 2016
      ✓ 
      Patent use: ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
      ✓ 
      Drug substance
  • Stable pharmaceutical composition
    Patent 6,465,477
    Issued: October 15, 2002
    Inventor(s): Toyojiro; Muramatsu & Katsumi; Mashita & Yasuo; Shinoda & Hironori; Sassa & Hiroyuki; Kawashima & Yoshio; Tanizawa & Hideatsu; Takeuchi
    Assignee(s): Kowa Company, Ltd. Nissan Chemical Industries, Ltd.
    Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4′-4″-fluorophenyl-2′-cyclopropyl-quinolin-3′-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.
    Patent expiration dates:
    • December 20, 2016
      ✓ 
      Drug product
  • Hyperlipemia therapeutic agent
    Patent 7,022,713
    Issued: April 4, 2006
    Inventor(s): Aoki; Taro & Yamaguchi; Junji & Sasaki; Yusuke
    Assignee(s): KOWA Co., Ltd. Nissan Chemical Industries, Ltd.
    The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients. According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.
    Patent expiration dates:
    • February 19, 2024
      ✓ 
      Patent use: ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 3, 2014 - NEW CHEMICAL ENTITY

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web1)